Associated Papers
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
Park S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2025
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
39097719 (PubMed )
Supplement: 12885_2024_12737_MOESM2_ESM.xlsx › Table_S1
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
38548752 (PubMed )
Supplement: 41467_2024_45594_MOESM4_ESM.xlsx › All
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.
Upadhyay VA et al.
Jco Precision Oncology, 2022
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M et al.
Nature Communications, 2021
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2020
Select a paper to view details